CA17140 for our Society

Action and Society

The content of this section is dedicated to all European and worldwide citizens and media who are interested in our Action, in the results we achieved and in how they could benefit from the activities performed within this Action.

"Our work performed during CA17140 was focused on on the development of new specificn nanosystems for cancer therapy and diagnosis. If ultimately proven successful, these nanosystems will contribute to the treatment and diagnosis of gliblastoma and osteosarcoma". Helena Tomas, Portugal
"Collaboration within CA17140 has allowed us to better understand how the important class of metallodrugs act in their biological activity and how to produce new agents for photodynamic therapies". Joao C. Lima, Portugal
"The use of a new class of nanosystems called aptadendrimers we studied in CA17140 for prostate cancer therapy has the goal to contribute, impact and increase life expectancy of patients with this disease and, by consequence, to improve the quality of life of their families that also suffer with them. Also, the share of knowledge between teams from Portugal and Spain contribute to research globalization and progress/development in science in Europe". Andre F. Rodriguez Miranda, STSM recipient, Portugal
"In CA17140 we investigated a therapeutic strategy based on pre-MIR150 G4 ligand complex nanosystems for treating non small cell lung cancer (NSCLCs). NSCLC is the leading cause of cancer associated mortality globally, with a low 5-year survival rate and with incidence project4ed to increase to 21.4 millions in 2030. Our research aims at enhancing NSCLC sensitivity to this novel therapy". Joana P. Rodriguez Figueiredo, STSM recipient, Portugal
"During the activity in CA17140 we developed new nanoformulations for the treatment of melanoma and provided new liposomes loaded with anticancer drugs that can be used as novel therapeutic approached in cancer patients". Jessica Lopez Nunes, STSM recipient, Portugal
"Collaboration within CA17140 has resulted in both a larger network and new product ideas. For NaDeNo this may potentially lead to improved production of our lead product candidate and novel pipeline products, which both may benefit cancer patients in the long term". Yrr Morch, NaDeNO SME, Norway
"CA17140 networking allowed me to investigate the ability of newly discovered bio-sourced molecules to be encapuslated into nanovectors and to be targeted and delivered to cancer cells. This might play an important role for the future development of naturally-based therapies and opens new ways in natural products exploitation and long-term scale development of new bio-sourced pharmaceutics". Aura Tintaru, STSM recipient, France
"Within CA17140 we have been able to establish a strong scientific network which will greatly contribute to our own products and technologies aimed at improving the public health of the European citizens". Mingxing Wei, C&O, Cellwax, SME, France
"The collaborations within CA17140 allowed us to discover a safe new nanotreatment for cancer treatment which is currently being tested and evaluated in pre-clinical models. If these tests will be successful, this new nanosystem could be moved to the clinic and constitute another weapon in cancer treatment." Jose A. Laz-Ruiz, STSM recipient, Spain

" CA17140 networking allowed us to gain fundamental knowledge on nanotransporters of anticancer drugs in order to generate improved chemotherapy in the future. Moreover, we established increased recognition of photodynamic therapy as an alternative approach to standard chemotherapy, and discovered new nanosystems to transport photosensitizers." Barbara Klajnert-Makulewicz, Poland

"In CA17140 we have been able to develop new drug delivery systems and formulated this nanosystems in collaboration with clinicians and industry. We are now ready to perform the clinical translation of these new therapeutics with the Labfit company." Carla Cruz, Portugal
"Neuroprotection agents are very important for different brain diseases, independent which kind of them can be used. In our lab, during CA17140 we have been able to search and study  specific Aβ(1-40) or Aβ(1-42) approaches: (i) anti-Alzheimer agent; (ii) digestive artificial organelles for Aβ(1-40) or Aβ(1-42) degradation; and (iii) neuroprotective agents based on biodegradable glycodendrimers. This results will greatly contribute to the understanding of neuropathologies and their treatments." Dietmar Appelhans, Germany
"Within CA17140 we have been able to produce nanocarriers modified by DNA aptamers for targeted drug delivery that minimize side effects of chemotherapeutics. When translated to the clinics, these systems will enhance the efficacy of chemotherapy in cancer treatment." Tibor Hianik, Slovakia
"As a results of CA7140, I think we will see a more stringent reduction of animal experiments in nano-drug development projects, which is also a general current trend in global science policies. I believe the advantages of my science in this regard has impacted the community, as measured by scientific discussions and complementary expertise to chemical experts.  The effect is well in line with recent update of FDA guidelines regarding prerequisites of preclinical studies for approving first in man testing." Ulf Kahlert, Germany
"Networks like CA17140 are instrumental to Increase the knowledge and advances of nanomedicine in therapy especially in cancer therapy, dealing with both production and application aspects, along with production and regulatory aims." Giovanni Tosi, Italy
"Networks like CA17140 can be create the basis for IP and from there SME/spin-off initiatives that can both benefit Europe in the area of nanomedicine as well a lead to new drugs/drug delivery systems with high impact on disease treatments." Jorn B. Christensen, Denmark
"The network established by CA17140 is based on an interdisciplinary collaboration between science and industry (business). This mutual knowledge-experience/experience-knowledge bridge is indispensable to generate new nanomedicines having an ultimate social impact." Ivanka D. Petrova-Doycheva, STSM recipient, Bulgaria
"Networking and STSMs as those performed within CA17140 allow to establish new scientific collaborations and open new job opportunities for young scientists across Europe, as it happened to me. After my STSM, I was contracted as a post doc in my STSM host institution in Ireland under an European project. This further allowed me to set up new collaborations and expand my research network." Esperanza Padin Gonzales, STSM recipient, Spain
"My activity in CA17140 allowed me to take the first steps towards a protocol to obtain pilot scale batches of a docetaxel-based nanomedicine. This will contribute to fulfill the needs of an industrial-scale of manufacturing of this type of cancer nanomedicine. Moreover, the protocols presents versatility to nano-formulate a variety of other chemotherapeutics." Claudia Martins, STSM recipient, Portugal
"In CA17140 we were able to develop new strategies for understanding the interactions between nanomedicines and biological membranes; moreover, only by networking we were able to uncover the effects of different nanoparticles on inflammation responses induced in vivo. These are key information for the safe formulation of new nanomedicines". Dominika Wrobel, STSM recipient, Czech Republic
"During CA17140 we discover that CD44v6 seems to behave as a stemness marker in colorectal cancer, being involved in tumor relapse and bad prognosis. Thus, the work we next performed on targeting CD44v6 with new nanoparticles functionalized with specific antibodies and encapsulating niclosamide appear a promising strategy to a more effective treatment of advanced colorectal cancer. We also empowered translational glioblastoma research by combining expertise in patinet-derived cancer spheroid/neuro-oncology." Bruno Sarmento, STSM recipient, Portugal
"Glioblastoma is a challenging disease with no satisfying treatment, low survival rate and high recurrence potential. Within CA17140, we have been able to establish a new platform based on conjugated nanoparticles with promising results in the treatment of this deadly cancer". Elham Poonaki, STSM recipient, Russia* (STSM performed before the beginning of the Russia-Ukraine conflict)
"Thanks to the networking within CA17140 we developed a nanomedicine-based approach with high potential for the future development of precision medicine in oncology and immunotherapy. These approaches could be one of the instruments of combined treatments to target aggressive and resistant tumors." Nadezhda Knauer, STSM recipient, Russia* (STSM performed before the beginning of the Russia-Ukraine conflict)
"In Ca17140 we were able to develop new mRNA-loaded nanoparticle as a potential new treatment of leukemia, one of the most common blood cancer". Giovanna Lollo, STSM recipient, France
"During CA17140 networking we have been able to devise a new strategy for systemic delivery of therapeutic agents by extracelluar vesicles for the treatment of prostate cancer. We are currently working on the issue of overcoming the barriers to clinical translation of these highly promising systems." Mariangela Garofolo, STSM recipient, Italy
"Pterygium is an ophthalmic pathology characterized by a progressive growth, able to invade  the cornea and to impair the visual function, in rare cases leading to blindness. Only in Italy one million people suffer from pterygium. Nowadays, current management strategies for pterygium imply surgical excision that is a complex and invasive procedure that most often results in the recurrence of a more clinically aggressive lesion than the initial one. In CA17140 we have identified a new potential non-invasive treatment of ptergyum which is currently under further study and development." Gianmarco Stati, STSM recipient, Italy
"Within CA17140 we joined our efforts in the discovery, study and possible translation of new effective nanomedicine-based treatments against mesothelioma." Lukasz Kuryk, STSM recipient, Poland
"Through the CA17140 networking we were able to develop a quick and non-invasive test kit to swiftly predict whether a given cancer could be resistant to a given treatment. According to the response, the treatment can be continued or another therapeutic regimen can be adopted." Dilara Buse Durdabak, STSM recipient, Turkey
"The collaboration within CA17140 allowed us to synthesize contamination-free, novel inorganic nanoparticles of controlled size and chemical composition as potential durg delivery systems". Ruixue Zhu, STSM recipient, Finland

"Within CA17140 we developed tools and procedures to evaluate the toxicological behavior of nanomaterials, as this constitutes an essential knowledge before the relevant nanoformulations can be tested in clinical trials". Natalia Fernandez-Bertolez, STSM recipient, Spain

"Jointed cooperation as the one realized in CA17140 are instrumental to build the multidisciplinary team required for developing nanomedicines. Only in this way we can bridge material and medical sciecnes, new technology platforms, and disease models better mimicking specific clinical conditions, while shaping the current regulatory framework to science-based standards. CA17140 has substantially contributed in generating the wealth of data required to grant marketing authorization of disruptive technologies required to treat cancer patients in the long term". Maria Eugenia Riveiro, Early Drug Development Group (E2DG), SME, France

"CA17140 has been a true material foundry, a crossroad of many disciplines all concurring in shaping the future of and paving the road for nanomedicines to the clinics. We trained more than 100 young European Researchers in all these fields and produces a plethora of new molecules, materials, kits and devices that - besides contributing to the general wealth of knowledge - are being tested as potential new therapeutic and diagnostic systems. Moreover, we also elaborated formal documents concerning the safety and regulations of nanomedicines and submitted these to the attention of the Health General Directorate of the European Commission, to enforce a safely and efficient journey of these innovative treatments from the bench to the patient bedside". Sabrina Pricl, Italy

European Cooperation in Science and Technology (COST) logo
Funded by the European Union